Agilus Diagnostics, one of India’s leading diagnostic service providers and a subsidiary of Fortis Healthcare, announced the launch of the Complete Care Vital Shape test suite (Lite, Core, and Ultra). This structured portfolio is designed for smarter weight management, early detection of insulin resistance, and long-term metabolic health monitoring — especially relevant amid rising global attention on GLP-1–based therapies for obesity.
India continues to witness a steep rise in obesity, with nearly one in four females and two in five males now overweight or obese. In urban populations, prevalence has reached 30–40%, driven by lifestyle and dietary changes. This growing burden underscores the need for comprehensive diagnostics that support prevention, guide clinical decision-making, and monitor long-term metabolic risks.
The Vital Shape panels offer tiered depth of assessment to detect metabolic and obesity-related risks early:
- Vital Shape Lite (72 parameters): Provides a strong baseline metabolic evaluation, including BMI, Comprehensive Metabolic Profile (CMP), eGFR for kidney health, CBC, lipid profile, free thyroid profile, HbA1c, fasting insulin, HOMA-IR for insulin resistance, FIB-4 for liver health, ferritin and iron studies for anemia, along with Vitamin D and Vitamin B12 status.
- Vital Shape Core (80 parameters): Includes all Lite parameters, plus deeper insights through hsCRP (cardiac inflammation), and additional markers of nutritional and metabolic health.
- Vital Shape Ultra (86 parameters): One of India’s most comprehensive obesity-focused test suites, adding leptin and adiponectin (metabolic signalling), amylase and lipase (pancreatitis risk), and PTH with calcium (bone and endocrine function), offering advanced insights into fatty liver, chronic inflammation and hormonal drivers of metabolic dysfunction.
Dr. Anand K, Managing Director & CEO, Agilus Diagnostics, said: “We are witnessing a global shift in obesity care, especially with the increasing use of GLP-1–based therapies. As clinical practices evolve, diagnostics must evolve with them. Complete Care Vital Shape empowers clinicians with comprehensive insights into insulin resistance, fatty liver, metabolic syndrome and cardiometabolic disorders. These conditions that lead to obesity often remain silent for years, and early detection is crucial for preventive and personalised care. This suite reinforces our commitment to supporting evidence-based decision-making at a time when patient expectations and scientific guidance are rapidly changing.”
Dr. Ajay Phadke, Director – Strategic Business Development, Agilus Diagnostics, added: “Over the last quarter, we have seen a sharp rise in enquiries for structured assessments around obesity management, high-insulin states and metabolic dysfunction. Complete Care Vital Shape positions Agilus among the select few offering such detailed, clinically oriented panels in this space. As the use of GLP-1 agonists increases, clinicians need deeper baseline evaluations and continuous monitoring to track metabolic risks — from fatty liver to cardiometabolic disorders. This suite is built precisely for those needs, and we will continue expanding the portfolio based on real-world evidence and clinical utility.”
As GLP-1 medications gain mainstream acceptance in obesity management, clinicians worldwide are underscoring the importance of baseline metabolic evaluations, ongoing monitoring, and early detection of risks before, during, and after therapy. With one of the world’s largest populations at risk for diabetes, cardiovascular disease, and fatty liver, India stands to benefit significantly from standardised diagnostic protocols. The Complete Care Vital Shape suite has been designed to support this emerging clinical need of setting the baseline for glp1 therapy and periodic monitoring for managing the efficacy.